id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0022,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry,Other,Guidance,2020-12-17T05:00:00Z,2020,12,2020-12-17T05:00:00Z,,2022-12-22T13:59:06Z,,0,0,09000064849a5cce
FDA-2014-D-1167-0021,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2020-12-17T05:00:00Z,2020,12,2020-12-17T05:00:00Z,,2020-12-17T19:19:44Z,2020-27810,0,0,09000064849a4518